The therapeutic activities of orally administered FK041were evaluated in mousemodels of systemic and local infections with a variety of bacteria and were compared with those of cefdinir (CFDN) and cefditoren pivoxil (CDTR-PI). FK041 exhibited potent therapeutic activity against lethal systemic infections induced by intraperitoneally inoculated Staphylococcus aureus, Escherichia coli, and Klebsiella pneumoniae with 50% effective doses (ED50) in the range of 0.20 to 0.36mg/kg and was more active than CFDNand CDTR-PI. This result correlated well with its in vitro activity. The therapeutic effects of FK041and reference drugs on murine local infections were evaluated in an in vivo pharmacokinetic model simulating human plasma concentrations for oral administration of 50mg, lOO mg, and 200 mg. Against murine subcutaneous abscess induced by S. aureus, FK041was as effective as CFDNand significantly more effective than CDTR-PIin reducing the number of recoverable viable bacteria in the skin at the infection sites. The efficacy of FK041against murine pneumonia with H. influenzae was comparable to that of CDTR-PIand was superior to that of CFDNin reducing viable bacteria activity in the lungs. These results strongly suggest that FK041 has potential for clinical use against various bacterial infections.
The therapeutic activities of orally administered FK041were evaluated in mousemodels of systemic and local infections with a variety of bacteria and were compared with those of cefdinir (CFDN) and cefditoren pivoxil (CDTR-PI). FK041 exhibited potent therapeutic activity against lethal systemic infections induced by intraperitoneally inoculated Staphylococcus aureus, Escherichia coli, and Klebsiella pneumoniae with 50% effective doses (ED50) in the range of 0.20 to 0.36mg/kg and was more active than CFDNand CDTR-PI. This result correlated well with its in vitro activity. The therapeutic effects of FK041and reference drugs on murine local infections were evaluated in an in vivo pharmacokinetic model simulating human plasma concentrations for oral administration of 50mg, lOO mg, and 200 mg. Against murine subcutaneous abscess induced by S. aureus, FK041was as effective as CFDNand significantly more effective than CDTR-PIin reducing the number of recoverable viable bacteria in the skin at the infection sites. The efficacy of FK041against murine pneumonia with H. influenzae was comparable to that of CDTR-PIand was superior to that of CFDNin reducing viable bacteria activity in the lungs. These results strongly suggest that FK041 has potential for clinical use against various bacterial infections.
FK041, a new cephem antibiotic for oral use, has been shownto have some advantages over the currently available oral cephalosporins1)2). For example, it demonstrated a potent and broad spectrum of activity against a wide variety of clinical isolates of Gram-positive and Gramnegative bacterial When compared with CFDNU'4), FK041 also displayed improved activities against clinically important major pathogens, including H. influenzae, in addition to more potent antibacterial activity, better oral absorbability, and excellent stability to /3-lactamase hydrolysis.
To evaluate its in vivo activity, the therapeutic effects of FK041on murine systemic infections were compared with those of cefdinir (CFDN)4) and cefditoren pivoxil (CDTR-PI)5). Moreover, in order to predict its clinical efficacy, the therapeutic effects of FK041 were compared with those of the reference drugs against local infection models in mice with an in vivo pharmacokinetic model in which 
Lethal Systemic Infection
The in vivo efficacy of FK041 was examined by a modification of the previously reported method4). Male ICR-strain mice were used in groups of 8. S. aureus Smith, E. coli 29, and K. pneumoniae 1 were cultured overnight 661 on Trypticase soy agar at 37°C. Each test strain was suspended in 5% bacteriological mucin (Nacalai Tesque Inc., Kyoto, Japan) to be given at about 1 to 5 minimumlethal dose. A cell suspension of 0.5 ml was injected intraperitoneally and the test antibiotics suspended in 0.5% methylcellulose solution were given orally in single dos£s 1 hour after challenge. The mice were observed for 4 days. The protective effect of the test drugs was expressed in terms of the 50% effective doses (ED50) estimated by the probit method6).
Therapeutic Effect in an In Vivo Pharmacokinetic Model
(1) Dose and dosing regimens: The doses and dosing schedules of the drugs were designed so that plasma concentrations in mice may approximate the time-related concentrations in humanplasma after oral administration of 50, 100, and 200 mg. Humanplasma concentrations of each antibiotic after lOOmgoral administration were referred to data reported previously7~9). The doses for oral administration with 50 and 200mg were calculated by multiplying each dose ratio by lOOmg. Since plasma clearance in mice was much faster than that in humans, frequent subcutaneous administration were necessary to reproduce the humanplasma concentrations in mice plasma. Each dose was calculated by a mathematical model10). The dosage regimens are shown in Fig. 1 and Table 1. (2) Subcutaneous abscess: Groups of 5 mice were used. S. aureus 41 precultured on brain heart infusion agar (Difco) at 37°C for 18hours was suspended in 2%Cytodex 1 (Pharmacia Biotech AB, Uppsala, Sweden), and 0.1 ml (4.6X 104cfu) was injected subcutaneously into the mice.
The infected mice were subcutaneouly treated with 13 administrations of the drugs, as shown in Table 1 , starting at 1 hour after infection at a site remote to the infection. supplemented with 5% Fildes enrichment (Oxoid) at 37°C for 1 8 hours in 5% CO2atmosphere was suspended in brain heart infusion broth, and 0.05 ml (2.8X l08 cfu) was intranasally inoculated in the anesthetized mice. The infected mice were subcutaneously treated with 13 administrations of the drugs, as shown in Table 1 , starting at 1.5hour after infection.
The mice were sacrificed at 7 and 24 hours after the initial dosing, and the lungs were aseptically removed. Each sample was homogenizedand the numberof viable bacteria was counted by the conventional plating method.
Statistical Analysis
Turkey-type multiple comparison was used to determine the significant differences between the drug-treated and 
Results and discussion

Therapeutic Effects of FK041 on Lethal Systemic Infection
The therapeutic effects of FK041 were compared with those of CFDN and CDTR-PI against lethal systemic infection models in mice induced by 3 clinically common pathogens ( Table 2 ). FK04 1 exhibited excellent therapeutic effects against all of the systemic infection models induced by S. aureus, E. coli, and K. pneumoniae with ED50s in the range of 0.20 to 0.36mg/kg, and FK041 was the most active of the test agents against these infection models. In our preceding paper on the in vitro evaluation of FK041, it was also shown to be superior to CFDNand CDTRagainst clinical isolates of S. aureus, E. coli, and K. pneumoniae. than that of FK041after orally administrated at same dose, the T-half of CDTR-PI is shorter than that of FK0417). When compared with the time above MICon the basis of each MIC, the time above MIC ofFK041 is longer than that of CDTR-PI (Data is not shown). The time above MIC is the pharmacodynamic parameter that best indicates the efficacy of /?-lactam10). This discrepancy may be attributed to the different pharmacokinetics of each drug.
Therapeutic Effects ofFK041 in an In Vivo Pharmacokinetic Model
The in vivo efficacy of FK041against lethal systemic infection in mice correlated well with its in vitro activity. This result, however, does not necessarily mean that FK041 is clinically effective against bacterial infections in human. If there is a discrepancy in pharmacokinetic properties between mice and humans, the results obtained in mice can not be readily extrapolated to man. In order to account for this possibility, and to predict efficacy in humans more accurately , we designed an in vivo pharmacokinetic model JULY 1999 in which drug concentrations in humanplasma are reproduced in mouseplasma10). The therapeutic activities of FK041 against experimental models of subcutaneous abscess and pneumoniawere evaluated with this in vivo pharmacokinetic model and were compared with those of CFDNand CDTR-PI. Fig. 1 shows plasma concentrations in humans after a single oral administration of lOOmg of each test drug and Table 1 indicates treatment regimens in mice to simulate the time-related concentrations in humanplasma.
Against subcutaneous abscess with S. aureus 47, FK041 exhibited a dose dependent therapeutic effect and significantly reduced the viable cell counts in the skin to 4.91, 3.97, and 3.49 loglO at the respective doses equivalent to 50, 100, and 200mg in humans, when compared with 6.82 log10 in the control mice at 24 hours after the initial dosing (Table 3 ). The therapeutic effect ofFK041 was significantly superior to that of CDTR-PI, which did not significantly reduce the viable cell counts at any dose tested. In addition, the number of recovered bacteria from infected mice treated with 50mg equivalent of FK041 was significantly lower than with CFDNat 24hours after the initial dosing. These Table 4 . Therapeutic effect of FK041 after oral dosing on pneumonia with
Haemophilus influenzae 300 1a in mice. Table 4 shows the efficacy of FK041 in a mouse model of pneumonia induced by H. influenzae. The viable cell counts in the lungs were significantly decreased to 5.33 and 5.23 loglO after a single oral administration of FK041 at the respective doses equivalent to 100 and 200mg in humans, when compared with 7.13 log10 in the control mice at 24hours after the initial dosing. FK041 was significantly superior to CFDNin reduction of the viable cell counts recovered from the infected mice treated with lOO mg equivalent at 7 hours after the initial dosing. There was no significant difference in the number of recovered bacteria between FK041 and CDTR-PI at any dose tested. These results suggest that oral treatment with FK041at lOO mg/day maybe effective against humanrespiratory infection with H. influenzae and that the therapeutic efficacy of FK041 may be superior to that of CFDN.
In conclusion, FK041 exhibited more potent therapeutic effects in several experimental infections in mice than CFDN, in accordance with the results of in vitro activity determinations, which indicated that FK041 was more potent than CFDNagainst a wide variety of Gram-positive and negative bacteria. These results suggest that FK041 maybe effective in the clinical treatment of bacterial infection.
